Semaglutide Effects in HFpEF

Introduction to Semaglutide Benefits

• Semaglutide 2.4 mg once weekly significantly improves heart failure symptoms, physical function, and reduces heart failure events in patients with obesity-related HFpEF, with or without type 2 diabetes, making it a disease-modifying therapy for this population 1, 2, 3

Guideline Recommendations

• The American Heart Association and American College of Cardiology acknowledge semaglutide's benefits in HFpEF with improvements in symptoms and exercise function 5, 6
• Semaglutide should be considered for persons with type 2 diabetes and HFpEF, particularly those with obesity 1

Safety and Clinical Implementation

• Slow dose titration improves tolerability 6
• Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common adverse events 6
• Monitoring should track KCCQ scores, weight, NYHA class, and consider loop diuretic dose adjustments as symptoms improve 4
• In a pre-specified analysis, 17% of semaglutide-treated patients had loop diuretic dose reductions vs 2% increase in placebo group 4